Pharmsynthez Of Russia, UK's Xenetic Begin MS Vaccine Trials
This article was originally published in PharmAsia News
Executive Summary
Russia's Pharmsynthez and co-developer Xenetic Biosciences of the UK have begun Russia clinical trials on their MyeloXea multiple sclerosis vaccine based on Xenetic's liposomal entrapment technology.